it is my understanding that this announcement from NCCN which is only guidelines ... is in fact neutral for TLX
at moment TLX cannot market Illuccix for patient selection but a customer could choose it and still claim reimbursement
im thinking the NCCN guidelines suggest all of the manufacturers can now be selected . novartis has issues currently and Lantheus is more difficult to have delivered on time every time ???
i wont really comment on the stock price, albeit disappointing
at some point, if you are a believer, you buy the business and walk away
Approval, page-47
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.45 |
Change
0.520(2.48%) |
Mkt cap ! $7.178B | |||
| Open | High | Low | Value | Volume |
| $20.83 | $21.50 | $20.80 | $17.54M | 824.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2037 | $21.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.50 | 12320 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |